Transcutaneous Auricular Vagal Nerve Stimulation Against Fatigue Syndrome in Patients with Long COVID: Results of the Randomized, Placebo-Controlled Clinical Pilot Trial COVIVA | Synapse
April 4, 2026Open Access
Transcutaneous Auricular Vagal Nerve Stimulation Against Fatigue Syndrome in Patients with Long COVID: Results of the Randomized, Placebo-Controlled Clinical Pilot Trial COVIVA
Key Points
To evaluate the efficacy of transcutaneous auricular vagal nerve stimulation on fatigue syndrome in long COVID patients.
Conducted a randomized, placebo-controlled clinical trial
Participants diagnosed with long COVID experiencing fatigue were enrolled
Transcutaneous auricular vagal nerve stimulation was administered to one group while the other received a placebo
The intervention group showed improvement in fatigue symptoms
Statistical analysis indicated significant differences between the treatment and placebo groups
Abstract
The trial was approved by the ethics committee (23/7798) and registered at the German Clinical Trials Register, identifier DRKS00031974.
Like
Bookmark
Share
View Full Paper
Like
Bookmark
Share
View Full Paper
Cite This Study
Gierthmuehlen et al. (Thu,) studied this question.